OT mobile menu

Search form


Breast Cancer Targets

BRCA Testing, Genetic Counseling Utilization in the Community Setting

Why are breast cancer patients not being referred to genetic counselors? Image © Pressmaster/Shutterstock.com


Breast Cancer Targets

A new population-based study is suggesting that there are significant racial disparities in gene expression profiling testing in women with breast cancer.

The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.

Scientists from Dana-Farber Cancer Institute found that a compound that can reverse the function of innate immune system cells—to fight tumors rather than encourage growth—caused breast tumors in mice to shrink and withdraw from distant metastases.

Scientists have discovered that African American patients with triple-negative breast cancer who carry a specific biomarker, nKIFC1, experience a dismal prognosis.

Researchers at the University of Illinois and collaborators in China have found a way to tag and target elusive cancers with small-molecule sugars by hijacking a cancer cell’s own metabolism.

Researchers at Johns Hopkins Kimmel Cancer Center have been studying the ability of a novel panel of cell-free DNA methylation markers to predict survival in women with metastatic breast cancer.

A secondary concern of breast cancer is the risk of the cancer cells spreading to the bones, causing severe pain and affecting quality of life. But, a new study has identified how bones get damaged and researchers from Huntsman Cancer Institute at the University of Utah are developing a new drug to mitigate this problem.


Subscribe to Breast Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.